Rabbit Monoclonal Antibodies Developed for Immunohistochemistry Applications
|
By LabMedica International staff writers Posted on 02 Mar 2010 |
|
A new range of rabbit monoclonal and polyclonal antibodies has been developed for immunohistochemistry (IHC) applications. A rabbit custom antibody service is also available.
Antibodies produced by rabbits are reported often to provide superior antigen recognition, greater specificity, and better consistency than those offered by mice. Rabbit antibodies can recognize specific antigens and epitopes that are not immunogenic in mice or rats. These antibodies can sometimes also offer higher working titers and may therefore help to lower laboratory costs. By using rabbit monoclonal antibodies (RMAbs), researchers can benefit from these unique qualities especially in the area of immunohistochemistry. Use of RMAbs technology provides critical information to researchers regarding the distribution and localization of biomarkers, and differentially expressed proteins in different parts of a biologic tissue.
AMSBIO (Abingdon, UK) offers a range of over 3,500 antibodies for immunohistochemistry including rabbit monoclonal, polyclonal, and mouse monoclonal antibodies (MAbs). Included in this range are antibodies that have been characterized to work on FFPE sections, renowned for their robust, highly sensitive, and specific characteristics. Many of these antibodies have been CE marked. The AMSBIO SP1 Estrogen Receptor antibody is now recommended as the gold standard by leading breast cancer experts and distributed worldwide.
AMS Biotechnology (AMSBIO) is a leading international provider of products and custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein, and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.
Related Links:
AMSBIO
Antibodies produced by rabbits are reported often to provide superior antigen recognition, greater specificity, and better consistency than those offered by mice. Rabbit antibodies can recognize specific antigens and epitopes that are not immunogenic in mice or rats. These antibodies can sometimes also offer higher working titers and may therefore help to lower laboratory costs. By using rabbit monoclonal antibodies (RMAbs), researchers can benefit from these unique qualities especially in the area of immunohistochemistry. Use of RMAbs technology provides critical information to researchers regarding the distribution and localization of biomarkers, and differentially expressed proteins in different parts of a biologic tissue.
AMSBIO (Abingdon, UK) offers a range of over 3,500 antibodies for immunohistochemistry including rabbit monoclonal, polyclonal, and mouse monoclonal antibodies (MAbs). Included in this range are antibodies that have been characterized to work on FFPE sections, renowned for their robust, highly sensitive, and specific characteristics. Many of these antibodies have been CE marked. The AMSBIO SP1 Estrogen Receptor antibody is now recommended as the gold standard by leading breast cancer experts and distributed worldwide.
AMS Biotechnology (AMSBIO) is a leading international provider of products and custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein, and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.
Related Links:
AMSBIO
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Automated Urinalysis Solution
UN-9000
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
